Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that it has licensed a drug response interpretation service from Seryx, LLC called Signature Genetics...
MedicAlert® has partnered with Seryx to offer the pharmacogenetic test called Signature Genetics to its product portfolio. Each year, millions of Americans fail to respond to their prescribed medications, or experience adverse reactions...
Seryx announced filing of a patent for a new pharmacogenetics/genomics information interpretation technology. The Seryx Drug Regimen Optimizer is designed to help physicians tailor medical treatment...
Seryx Inc. announced today that it has licensed its innovative Pharmacogenetics technology, Signature Genetics™, for the Asia/Pacific Rim markets. Under the agreement, Seryx Asia, a Singaporean company...
